Clinical Trial

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

Available
View on ClinicalTrials.gov →
Summary
REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-29; most recent amendment 2026-03-18.
Status change: Temporarily Not Available → Available 2026-03-18
Trial Details
NCT Number NCT07332338
Lead Sponsor StemCyte, Inc.
Conditions Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID, Chronic Fatigue, Chronic Fatigue Symptoms, Fatigue Post Viral
Updated on ClinicalTrials.gov 2026-03-23